Association of per- and polyfluoroalkyl substances with the antioxidant bilirubin across pregnancy
- PMID: 39097204
- PMCID: PMC11866431
- DOI: 10.1016/j.freeradbiomed.2024.07.037
Association of per- and polyfluoroalkyl substances with the antioxidant bilirubin across pregnancy
Abstract
Background: In mechanistic and preliminary human studies, prenatal exposure to per- and polyfluoroalkyl substances (PFAS) is associated with oxidative stress, a potential contributor to maternal liver disease. Bilirubin is an endogenous antioxidant abundant in the liver that may serve as a physiological modulator of oxidative stress in pregnant people. Hence, our objective was to estimate the association between repeated measures of PFAS and bilirubin during pregnancy.
Methods: The study population included 332 participants in the Atlanta African American Maternal-Child Cohort between 2014 and 2020. Serum samples were collected up to two times (early pregnancy: 6-18 gestational weeks; late pregnancy: 21-36 gestational weeks) for the measurement of perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and total bilirubin. We analyzed single PFAS with linear mixed effect regression and a mixture of the four PFAS with quantile g-computation. Models were repeated with a multiplicative interaction term to explore effect modification by study visit.
Results: Overall, PFHxS was positively associated with bilirubin (β = 0.08, 95 % CI = 0.01, 0.15). We also found during late pregnancy, there was a positive association of PFHxS and the PFAS mixture with bilirubin (β = 0.12, 95 % CI = 0.02, 0.22; ψ = 0.19, 95 % CI = 0.03, 0.34, respectively). Finally, study visit modified the PFOA-bilirubin association (interaction p-value = 0.09), which was greater during early pregnancy (β = 0.08, 95 % CI = 0.01, 0.15).
Conclusion: In a prospective cohort of pregnant African Americans, an increase in PFOA, PFHxS, and the PFAS mixture was associated with an increase in bilirubin. Our results suggest that, depending on pregnancy stage, prenatal PFAS exposure disrupts the maternal liver antioxidant capacity.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J Expo Sci Environ Epidemiol. 2019;29(2):131–47. Epub 2018/11/25. doi: 10.1038/s41370-018-0094-1. - DOI - PMC - PubMed
-
- Carlson LM, Angrish M, Shirke AV, Radke EG, Schulz B, Kraft A, Judson R, Patlewicz G, Blain R, Lin C, Vetter N, Lemeris C, Hartman P, Hubbard H, Arzuaga X, Davis A, Dishaw LV, Druwe IL, Hollinger H, Jones R, Kaiser JP, Lizarraga L, Noyes PD, Taylor M, Shapiro AJ, Williams AJ, Thayer KA. Systematic Evidence Map for Over One Hundred and Fifty Per- and Polyfluoroalkyl Substances (PFAS). Environ Health Perspect. 2022;130(5):56001. Epub 20220517. doi: 10.1289/EHP10343. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- R01 NR014800/NR/NINR NIH HHS/United States
- U2C ES026542/ES/NIEHS NIH HHS/United States
- P50 ES026071/ES/NIEHS NIH HHS/United States
- U2C OD023375/OD/NIH HHS/United States
- R01 MD009064/MD/NIMHD NIH HHS/United States
- R01 MD009746/MD/NIMHD NIH HHS/United States
- R21 ES032117/ES/NIEHS NIH HHS/United States
- U2C ES026560/ES/NIEHS NIH HHS/United States
- P30 ES019776/ES/NIEHS NIH HHS/United States
- R24 ES029490/ES/NIEHS NIH HHS/United States
- U24 ES029490/ES/NIEHS NIH HHS/United States
- T32 ES012870/ES/NIEHS NIH HHS/United States
- UH3 OD023318/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical